DeCODE Genetics Moves Heart Attack Prevention Candidate Into Phase IIb
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive Phase IIa results have encouraged the biopharma to move forward with additional testing of the leukotriene A4 hydrolase inhibitor.